公开(公告)号：US5510418A

公开(公告)日：1996-04-23

申请号：US146843

申请日：1993-11-03

Applicant: Woonza M. Rhee ,  Richard A. Berg

Inventor： Woonza M. Rhee ,  Richard A. Berg

IPC: A61L27/00 ,  A61F2/00 ,  A61F2/06 ,  A61K38/00 ,  A61K47/48 ,  A61L24/10 ,  A61L26/00 ,  A61L27/18 ,  A61L27/20 ,  A61L27/24 ,  A61L27/26 ,  A61L27/34 ,  A61L27/44 ,  A61L27/54 ,  A61L29/04 ,  A61L29/06 ,  A61L29/16 ,  A61L31/04 ,  A61L31/10 ,  A61L31/12 ,  C07K14/495 ,  C07K14/78 ,  C08B37/00 ,  C08B37/08 ,  C08H1/06 ,  C08L89/06 ,  C09J189/06 ,  C08G63/91

CPC classification number: A61K47/48215 ,  A61K47/4823 ,  A61K47/48292 ,  A61L24/102 ,  A61L26/0033 ,  A61L27/18 ,  A61L27/20 ,  A61L27/24 ,  A61L27/26 ,  A61L27/34 ,  A61L27/44 ,  A61L27/54 ,  A61L29/043 ,  A61L29/045 ,  A61L29/06 ,  A61L29/16 ,  A61L31/041 ,  A61L31/042 ,  A61L31/044 ,  A61L31/10 ,  A61L31/125 ,  C07K14/495 ,  C07K14/78 ,  C08B37/0069 ,  C08B37/0072 ,  C08H1/06 ,  C08L89/06 ,  C09J189/06 ,  A61F2/07 ,  A61F2310/00365 ,  A61K38/00 ,  A61L2300/236 ,  A61L2300/252 ,  A61L2300/414 ,  A61L2300/802 ,  A61L2430/16 ,  Y10S525/937

Abstract: Pharmaceutically acceptable, nonimmunogenic compositions are formed by covalently binding glycosaminoglycans or derivatives thereof, to hydrophilic synthetic polymers via specific types of chemical bonds to provide biocompatible conjugates. Useful glycosaminoglycans include hyaluronic acid, the chondroitin sulfates, keratan sulfate, chitin and heparin, each of which is chemically derivatized to react with a hydrophilic synthetic polymer. The conjugate comprising a glycosaminoglycan covalently bound to a hydrophilic synthetic polymer may be further bound to collagen to form a three component conjugate having different properties. The hydrophilic synthetic polymer may be polyethylene glycol and derivatives thereof having an average molecular weight over a range of from about 100 to about 100,000. The compositions may include other components such as fluid, pharmaceutically acceptable carriers to form injectable formulations, and/or biologically active proteins such as growth factors or cytokines. The conjugates of the invention generally contain large amounts of water when formed. The conjugates can be dehydrated to form a relatively solid implant for use in hard tissue augmentation. The dehydrated, solid implant can further be ground into particles which can be suspended in a non-aqueous fluid and injected into a living being (preferably human) for soft tissue augmentation. Once in place, the solid implants or particles rehydrate and expand in size approximately three- to five-fold.

公开(公告)号：US5476666A

公开(公告)日：1995-12-19

申请号：US434725

申请日：1995-05-04

Applicant: Woonza M. Rhee ,  Richard A. Berg

Inventor： Woonza M. Rhee ,  Richard A. Berg

IPC: A61L27/00 ,  A61F2/00 ,  A61F2/06 ,  A61K38/00 ,  A61K47/48 ,  A61L24/10 ,  A61L26/00 ,  A61L27/18 ,  A61L27/20 ,  A61L27/24 ,  A61L27/26 ,  A61L27/34 ,  A61L27/44 ,  A61L27/54 ,  A61L29/04 ,  A61L29/06 ,  A61L29/16 ,  A61L31/04 ,  A61L31/10 ,  A61L31/12 ,  C07K14/495 ,  C07K14/78 ,  C08B37/00 ,  C08B37/08 ,  C08H1/06 ,  C08L89/06 ,  C09J189/06 ,  A61K9/14

CPC classification number: A61K47/48215 ,  A61K47/4823 ,  A61K47/48292 ,  A61L24/102 ,  A61L26/0033 ,  A61L27/18 ,  A61L27/20 ,  A61L27/24 ,  A61L27/26 ,  A61L27/34 ,  A61L27/44 ,  A61L27/54 ,  A61L29/043 ,  A61L29/045 ,  A61L29/06 ,  A61L29/16 ,  A61L31/041 ,  A61L31/042 ,  A61L31/044 ,  A61L31/10 ,  A61L31/125 ,  C07K14/495 ,  C07K14/78 ,  C08B37/0069 ,  C08B37/0072 ,  C08H1/06 ,  C08L89/06 ,  C09J189/06 ,  A61F2/07 ,  A61F2310/00365 ,  A61K38/00 ,  A61L2300/236 ,  A61L2300/252 ,  A61L2300/414 ,  A61L2300/802 ,  A61L2430/16 ,  Y10S525/937

Abstract: Pharmaceutically acceptable, nonimmunogenic compositions are formed by covalently binding glycosaminoglycans or derivatives thereof, to hydrophilic synthetic polymers via specific types of chemical bonds to provide biocompatible conjugates. Useful glycosaminoglycans include hyaluronic acid, the chondroitin sulfates, keratan sulfate, chitin and heparin, each of which is chemically derivatized to react with a hydrophilic synthetic polymer. The conjugate comprising a glycosaminoglycan covalently bound to a hydrophilic synthetic polymer may be further bound to collagen to form a three component conjugate having different properties. The hydrophilic synthetic polymer may be polyethylene glycol and derivatives thereof having an average molecular weight over a range of from about 100 to about 100,000. The compositions may include other components such as fluid, pharmaceutically acceptable carriers to form injectable formulations, and/or biologically active proteins such as growth factors or cytokines. The conjugates of the invention generally contain large amounts of water when formed. The conjugates can be dehydrated to form a relatively solid implant for use in hard tissue augmentation. The dehydrated, solid implant can further be ground into particles which can be suspended in a non-aqueous fluid and injected into a living being (preferably human) for soft tissue augmentation. Once in place, the solid implants or particles rehydrate and expand in size approximately three- to five-fold.

Abstract translation: 药学上可接受的非免疫原性组合物通过将糖胺聚糖或其衍生物与亲水性合成聚合物共价结合而形成，通过特定类型的化学键提供生物相容性缀合物。 有用的糖胺聚糖包括透明质酸，硫酸软骨素，硫酸角质素，几丁质和肝素，其中每一种都被化学衍生以与亲水性合成聚合物反应。 共价结合亲水性合成聚合物的糖胺聚糖的缀合物可以进一步与胶原结合，形成具有不同性质的三组分共轭物。 亲水性合成聚合物可以是平均分子量在约100至约100,000范围内的聚乙二醇及其衍生物。 组合物可以包括其它组分如流体，药学上可接受的载体以形成可注射制剂，和/或生物活性蛋白如生长因子或细胞因子。 当形成时，本发明的共轭物通常含有大量的水。 可以将缀合物脱水以形成用于硬组织增加的相对固体植入物。 脱水的固体植入物可以进一步研磨成可以悬浮在非水性流体中的颗粒，并注入到生物体（优选人）中用于软组织增加。 一旦到位，固体植入物或颗粒再水化并且尺寸扩大约三至五倍。

公开(公告)号：US5470911A

公开(公告)日：1995-11-28

申请号：US433656

申请日：1995-05-04

Applicant: Woonza M. Rhee ,  Richard A. Berg

Inventor： Woonza M. Rhee ,  Richard A. Berg

IPC: A61L27/00 ,  A61F2/00 ,  A61F2/06 ,  A61K38/00 ,  A61K47/48 ,  A61L24/10 ,  A61L26/00 ,  A61L27/18 ,  A61L27/20 ,  A61L27/24 ,  A61L27/26 ,  A61L27/34 ,  A61L27/44 ,  A61L27/54 ,  A61L29/04 ,  A61L29/06 ,  A61L29/16 ,  A61L31/04 ,  A61L31/10 ,  A61L31/12 ,  C07K14/495 ,  C07K14/78 ,  C08B37/00 ,  C08B37/08 ,  C08H1/06 ,  C08L89/06 ,  C09J189/06 ,  C08G63/48 ,  C08G63/91 ,  C08G63/40

CPC classification number: A61K47/48215 ,  A61K47/4823 ,  A61K47/48292 ,  A61L24/102 ,  A61L26/0033 ,  A61L27/18 ,  A61L27/20 ,  A61L27/24 ,  A61L27/26 ,  A61L27/34 ,  A61L27/44 ,  A61L27/54 ,  A61L29/043 ,  A61L29/045 ,  A61L29/06 ,  A61L29/16 ,  A61L31/041 ,  A61L31/042 ,  A61L31/044 ,  A61L31/10 ,  A61L31/125 ,  C07K14/495 ,  C07K14/78 ,  C08B37/0069 ,  C08B37/0072 ,  C08H1/06 ,  C08L89/06 ,  C09J189/06 ,  A61F2/07 ,  A61F2310/00365 ,  A61K38/00 ,  A61L2300/236 ,  A61L2300/252 ,  A61L2300/414 ,  A61L2300/802 ,  A61L2430/16 ,  Y10S525/937

Abstract: Pharmaceutically acceptable, nonimmunogenic compositions are formed by covalently binding glycosaminoglycans or derivatives thereof, to hydrophilic synthetic polymers via specific types of chemical bonds to provide biocompatible conjugates. Useful glycosaminoglycans include hyaluronic acid, the chondroitin sulfates, keratan sulfate, chitin and heparin, each of which is chemically derivatized to react with a hydrophilic synthetic polymer. The conjugate comprising a glycosaminoglycan covalently bound to a hydrophilic synthetic polymer may be further bound to collagen to form a three component conjugate having different properties. The hydrophilic synthetic polymer may be polyethylene glycol and derivatives thereof having an average molecular weight over a range of from about 100 to about 100,000. The compositions may include other components such as fluid, pharmaceutically acceptable carriers to form injectable formulations, and/or biologically active proteins such as growth factors or cytokines. The conjugates of the invention generally contain large amounts of water when formed. The conjugates can be dehydrated to form a relatively solid implant for use in hard tissue augmentation. The dehydrated, solid implant can further be ground into particles which can be suspended in a non-aqueous fluid and injected into a living being (preferably human) for soft tissue augmentation. Once in place, the solid implants or particles rehydrate and expand in size approximately three- to five-fold.

公开(公告)号：US5328955A

公开(公告)日：1994-07-12

申请号：US922541

申请日：1992-07-30

Applicant: Woonza Rhee ,  Donald G. Wallace ,  Alan S. Michaels ,  Ramon A. Burns, Jr. ,  Louis Fries ,  Frank DeLustro ,  Hanne Bentz

Inventor： Woonza Rhee ,  Donald G. Wallace ,  Alan S. Michaels ,  Ramon A. Burns, Jr. ,  Louis Fries ,  Frank DeLustro ,  Hanne Bentz

IPC: A61L27/00 ,  A61F2/00 ,  A61F2/06 ,  A61K38/00 ,  A61K38/17 ,  A61K38/21 ,  A61K38/22 ,  A61K45/06 ,  A61K47/48 ,  A61L15/22 ,  A61L24/10 ,  A61L26/00 ,  A61L27/18 ,  A61L27/20 ,  A61L27/24 ,  A61L27/26 ,  A61L27/34 ,  A61L27/44 ,  A61L27/54 ,  A61L29/04 ,  A61L29/06 ,  A61L29/16 ,  A61L31/04 ,  A61L31/10 ,  A61L31/12 ,  A61P17/00 ,  A61P43/00 ,  C07K14/495 ,  C07K14/78 ,  C08B37/08 ,  C08G81/00 ,  C08H1/00 ,  C08H1/06 ,  C08L89/00 ,  C08L89/06 ,  C09J189/06 ,  G02B1/04 ,  C08G63/48 ,  A61F13/00

CPC classification number: C08L89/06 ,  A61K47/48215 ,  A61K47/4823 ,  A61K47/48292 ,  A61L15/225 ,  A61L24/102 ,  A61L26/0033 ,  A61L27/18 ,  A61L27/20 ,  A61L27/24 ,  A61L27/26 ,  A61L27/34 ,  A61L27/44 ,  A61L27/54 ,  A61L29/043 ,  A61L29/045 ,  A61L29/06 ,  A61L29/16 ,  A61L31/041 ,  A61L31/042 ,  A61L31/044 ,  A61L31/10 ,  A61L31/125 ,  C07K14/495 ,  C07K14/78 ,  C08B37/0069 ,  C08B37/0072 ,  C08H1/06 ,  C09J189/06 ,  G02B1/043 ,  A61F2/07 ,  A61F2310/00365 ,  A61K38/00 ,  A61L2300/252 ,  A61L2300/414 ,  A61L2300/426 ,  A61L2300/62 ,  A61L2300/802 ,  A61L2430/16 ,  Y10S525/937

Abstract: Pharmaceutically acceptable, non-immunogenic compositions are formed by covalently binding atelopeptide collagen to pharmaceutically pure, synthetic, hydrophilic polymers via specific types of chemical bonds to provide collagen/polymer conjugates. The atelopeptide collagen can be type I, type II or type III and may be fibrillar or non-fibrillar. The synthetic hydrophilic polymer may be polyethylene glycol and derivatives thereof having a weight average molecular weight over a range of from about 100 to about 20,000. The compositions may include other components such as liquid, pharmaceutically acceptable, carriers to form injectable formulations, and/or biologically active proteins such as growth factors. The collagen-polymer conjugates of the invention generally contain large amounts of water when formed. The conjugates can be dehydrated to form a relatively solid object. The dehydrated, solid object can be ground into particles which can be suspended in a non-aqueous fluid such as an oil and injected into a living being for the purpose of providing soft tissue augmentation. Once in place, the particles rehydrate and expand in size five fold or more.

Abstract translation: 药学上可接受的非免疫原性组合物通过经由特定类型的化学键共价结合肽肽胶原与药学​​纯合成的亲水性聚合物形成，以提供胶原/聚合物共轭物。 糖尿病胶原可以是I型，II型或III型，并且可以是纤维状或非纤维状的。 合成亲水性聚合物可以是重均分子量在约100至约20,000范围内的聚乙二醇及其衍生物。 组合物可以包括其它组分，例如液体，药学上可接受的，载体以形成可注射制剂，和/或生物活性蛋白质例如生长因子。 当形成时，本发明的胶原 - 聚合物共轭物通常含有大量的水。 可以将共轭物脱水形成相对固体的物体。 脱水的固体可以被研磨成可以悬浮在诸如油之类的非水性流体中的颗粒，并注入活体以提供软组织增加。 一旦就位，颗粒再水合并扩大五倍以上。

公开(公告)号：US5292802A

公开(公告)日：1994-03-08

申请号：US985680

申请日：1992-12-02

Applicant: Woonza Rhee ,  Kimberly McCullough

Inventor： Woonza Rhee ,  Kimberly McCullough

IPC: A61L27/00 ,  A61F2/00 ,  A61F2/06 ,  A61K38/00 ,  A61K38/17 ,  A61K38/21 ,  A61K38/22 ,  A61K45/06 ,  A61K47/48 ,  A61L15/22 ,  A61L24/10 ,  A61L26/00 ,  A61L27/18 ,  A61L27/20 ,  A61L27/24 ,  A61L27/26 ,  A61L27/34 ,  A61L27/44 ,  A61L27/54 ,  A61L29/04 ,  A61L29/06 ,  A61L29/16 ,  A61L31/04 ,  A61L31/10 ,  A61L31/12 ,  A61P17/00 ,  A61P43/00 ,  C07K14/495 ,  C07K14/78 ,  C08B37/08 ,  C08G81/00 ,  C08H1/00 ,  C08H1/06 ,  C08L89/00 ,  C08L89/06 ,  C09J189/06 ,  G02B1/04 ,  C08G63/48 ,  C08G63/91

CPC classification number: C08L89/06 ,  A61K47/48215 ,  A61K47/4823 ,  A61K47/48292 ,  A61L15/225 ,  A61L24/102 ,  A61L26/0033 ,  A61L27/18 ,  A61L27/20 ,  A61L27/24 ,  A61L27/26 ,  A61L27/34 ,  A61L27/44 ,  A61L27/54 ,  A61L29/043 ,  A61L29/045 ,  A61L29/06 ,  A61L29/16 ,  A61L31/041 ,  A61L31/042 ,  A61L31/044 ,  A61L31/10 ,  A61L31/125 ,  C07K14/495 ,  C07K14/78 ,  C08B37/0069 ,  C08B37/0072 ,  C08H1/06 ,  C09J189/06 ,  G02B1/043 ,  A61F2/07 ,  A61F2310/00365 ,  A61K38/00 ,  A61L2300/252 ,  A61L2300/414 ,  A61L2300/426 ,  A61L2300/62 ,  A61L2300/802 ,  A61L2430/16 ,  Y10S525/937

Abstract: Medical articles in the form of tubes are formed by covalently binding collagen to pharmaceutically pure, synthetic, hydrophilic polymers via specific types of chemical bonds to provide collagen/polymer conjugate formulations which are used to make the tubes. The collagen may be recombinantly produced human collagen or collagen extracted from any source, such as a bovine or human placental source, and purified and can be type I, type II or type III and may be fibrillar or non-fibrillar. The synthetic hydrophilic polymer may be polyethylene glycol and derivatives thereof having a weight average molecular weight over a range of from about 100 to about 20,000. The tube can be designed to incorporate other components such as liquid, pharmaceutically acceptable, carriers, and/or biologically active proteins such as growth factors or cytokines. The tubes contain large amounts of water when extruded and then may be dehydrated to form relatively solid but flexible tubes which can be easily stored. The tubes can be surgically implanted and attached to, or implanted within, a channel in a mammal for the purpose of repairing the channel. The tubes can be used to repair a wide range of different types of channels including but not limited to veins and arteries.

Abstract translation: 管形式的医疗制品通过特定类型的化学键将胶原蛋白共价结合到药物纯合成的亲水性聚合物上形成，以提供用于制备管的胶原/聚合物缀合物制剂。 胶原蛋白可以是重组产生的人胶原蛋白或从任何来源例如牛或人胎盘来源提取的胶原蛋白，并且被纯化并且可以是I型，II型或III型，并且可以是纤维状或非纤维状的。 合成亲水性聚合物可以是重均分子量在约100至约20,000范围内的聚乙二醇及其衍生物。 管可以被设计成结合其它成分，例如液体，药学上可接受的，载体和/或生物活性蛋白质，例如生长因子或细胞因子。 管子在挤出时含有大量的水，然后可以脱水以形成相对固体但柔性的管子，这些容器可容易地储存。 为了修复通道，管可以手术植入和附着到哺乳动物的通道内或植入哺乳动物的通道内。 管可用于修复各种不同类型的通道，包括但不限于静脉和动脉。

公开(公告)号：US20140356451A1

公开(公告)日：2014-12-04

申请号：US13903878

申请日：2013-05-28

Applicant: MiMedx Group, Inc.

Inventor： Thomas J. Koob

IPC: A61K47/48

CPC classification number: A61K47/48292 ,  A61K47/48776 ,  A61K47/6435 ,  A61K47/6901

Abstract: Provided herein are biocompatible polymer conjugates comprising a biologically compatible polymer covalently bound to a biologically compatible chelator moiety, which in turn are optionally bound, reversibly, to pharmacologically active metal ions. The biologically compatible polymer may comprise of modified placental tissue grafts composed of at least one membrane, capable of recruiting stem cells in vivo and in vitro.

Abstract translation: 本文提供了生物相容性聚合物缀合物，其包含与生物相容的螯合剂部分共价结合的生物相容性聚合物，其又可任选地结合到药理活性金属离子上。 生物相容的聚合物可包含由能够在体内和体外募集干细胞的至少一个膜组成的修饰的胎盘组织移植物。

公开(公告)号：US20140142041A1

公开(公告)日：2014-05-22

申请号：US13815834

申请日：2013-03-15

Applicant: MiMedx Group, Inc.

Inventor： Thomas J. Koob

IPC: A61K47/48

CPC classification number: A61K47/48292 ,  A61K31/282 ,  A61K31/555 ,  A61K33/24 ,  A61K47/6435 ,  A61K47/6953 ,  C07K14/78 ,  C12N2533/54

Abstract: The disclosure describes collagen constructs comprising anticancer agents, preferably, platinum, and related methods.

Abstract translation: 本公开描述了包含抗癌剂，优选铂的胶原构建体和相关方法。

公开(公告)号：US6132729A

公开(公告)日：2000-10-17

申请号：US9217

申请日：1998-01-20

Applicant: Philip E. Thorpe ,  Steven W. King ,  Boning Gao

Inventor： Philip E. Thorpe ,  Steven W. King ,  Boning Gao

IPC: A61K45/00 ,  A61K38/00 ,  A61K47/48 ,  A61P7/02 ,  A61P35/00 ,  A61K39/00 ,  A61K39/395 ,  C07K14/00 ,  C07K35/14

CPC classification number: A61K47/48423 ,  A61K47/48292 ,  Y10S514/834 ,  Y10S530/827 ,  Y10S530/829

Abstract: The invention embodies the surprising discovery that Tissue Factor (TF) compositions and variants thereof specifically localize to the blood vessels within a vascularized tumor following systemic administration. The invention therefore provides methods and compositions comprising coagulation-deficient Tissue Factor for use in effecting specific coagulation and for use in tumor treatment. The TF compositions and methods of present invention may be used alone, as TF conjugates with improved half-life, or in combination with other agents, such as conventional chemotherapeutic drugs, targeted immunotoxins, targeted coaguligands, and/or in combination with Factor VIIa (FVIIa) or FVII activators.

Abstract translation: 本发明体现了惊人的发现：组织因子（TF）组合物及其变体在全身给药后特异性定位于血管化肿瘤内的血管。 因此，本发明提供了用于实现特异性凝结和用于肿瘤治疗的凝血缺陷组织因子的方法和组合物。 本发明的TF组合物和方法可以单独使用，作为具有改善的半衰期的TF缀合物，或与其它试剂（例如常规化学治疗药物，靶向免疫毒素，靶向凝固配体）和/或与因子VIIa组合 FVIIa）或FVII激活剂。

公开(公告)号：US5654267A

公开(公告)日：1997-08-05

申请号：US347942

申请日：1994-11-30

Applicant: Kristiina Vuori ,  Erkki I. Ruoslahti

Inventor： Kristiina Vuori ,  Erkki I. Ruoslahti

IPC: A61K38/00 ,  A61K38/22 ,  A61K38/28 ,  A61K38/39 ,  A61K47/48 ,  A61L26/00 ,  A61P17/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/49 ,  C07K14/54 ,  C07K14/62 ,  C07K14/65 ,  C07K14/78 ,  C07K17/02 ,  C07K17/10 ,  C12N5/00

CPC classification number: C12N5/0068 ,  A61K38/39 ,  A61K47/48292 ,  A61L26/0047 ,  A61L26/0052 ,  C07K14/78 ,  C07K2319/00 ,  C12N2533/50 ,  C12N2533/70 ,  C12N2533/80

Abstract: The present invention provides compositions and methods for promoting cell migration and tissue regeneration. The composition contains a ligand for the .alpha..sub.v .beta..sub.3 integrin and a ligand for the insulin receptor, the PDGF receptor, the IL-4 receptor, or the IGF receptor, combined in a matrix. The combination of .alpha..sub.v .beta..sub.3 ligand and growth factor produces an unexpected synergistic effect in enhancing wound healing compared with the effect of each component separately. The present invention also provides a method of wound healing and a method of inducing tissue regeneration by applying the compositions of the present invention to the site of the wound.

Abstract translation: 本发明提供促进细胞迁移和组织再生的组合物和方法。 组合物包含αvβ3整联蛋白的配体和胰岛素受体的配体，PDGF受体，IL-4受体或IGF受体组合在基质中。 与每个组分的作用相比，αvβ3配体和生长因子的组合在增强伤口愈合方面产生了意想不到的协同效应。 本发明还提供了一种伤口愈合方法，以及通过将本发明的组合物应用于伤口部位来诱导组织再生的方法。

公开(公告)号：US5550188A

公开(公告)日：1996-08-27

申请号：US478510

申请日：1995-06-07

Applicant: Woonza Rhee ,  Donald G. Wallace ,  Alan S. Michaels ,  Ramon A. Burns, Jr. ,  Louis Fries ,  Frank DeLustro ,  Hanne Bentz

Inventor： Woonza Rhee ,  Donald G. Wallace ,  Alan S. Michaels ,  Ramon A. Burns, Jr. ,  Louis Fries ,  Frank DeLustro ,  Hanne Bentz

IPC: A61L27/00 ,  A61F2/00 ,  A61F2/06 ,  A61K38/00 ,  A61K38/17 ,  A61K38/21 ,  A61K38/22 ,  A61K45/06 ,  A61K47/48 ,  A61L15/22 ,  A61L24/10 ,  A61L26/00 ,  A61L27/18 ,  A61L27/20 ,  A61L27/24 ,  A61L27/26 ,  A61L27/34 ,  A61L27/44 ,  A61L27/54 ,  A61L29/04 ,  A61L29/06 ,  A61L29/16 ,  A61L31/04 ,  A61L31/10 ,  A61L31/12 ,  A61P17/00 ,  A61P43/00 ,  C07K14/495 ,  C07K14/78 ,  C08B37/08 ,  C08G81/00 ,  C08H1/00 ,  C08H1/06 ,  C08L89/00 ,  C08L89/06 ,  C09J189/06 ,  G02B1/04 ,  G02C7/04

CPC classification number: C08L89/06 ,  A61K47/48215 ,  A61K47/4823 ,  A61K47/48292 ,  A61L15/225 ,  A61L24/102 ,  A61L26/0033 ,  A61L27/18 ,  A61L27/20 ,  A61L27/24 ,  A61L27/26 ,  A61L27/34 ,  A61L27/44 ,  A61L27/54 ,  A61L29/043 ,  A61L29/045 ,  A61L29/06 ,  A61L29/16 ,  A61L31/041 ,  A61L31/042 ,  A61L31/044 ,  A61L31/10 ,  A61L31/125 ,  C07K14/495 ,  C07K14/78 ,  C08B37/0069 ,  C08B37/0072 ,  C08H1/06 ,  C09J189/06 ,  G02B1/043 ,  A61F2/07 ,  A61F2310/00365 ,  A61K38/00 ,  A61L2300/252 ,  A61L2300/414 ,  A61L2300/426 ,  A61L2300/62 ,  A61L2300/802 ,  A61L2430/16 ,  Y10S525/937

Abstract: Pharmaceutically acceptable, non-immunogenic compositions are formed by covalently binding atelopeptide collagen to pharmaceutically pure, synthetic, hydrophilic polymers via specific types of chemical bonds to provide collagen/polymer conjugates. The atelopeptide collagen can be type I, type II or type III and may be fibrillar or non-fibrillar. The synthetic hydrophilic polymer may be polyethylene glycol and derivatives thereof having a weight average molecular weight over a range of from about 100 to about 20,000. The compositions may include other components such as liquid, pharmaceutically acceptable, carriers to form injectable formulations, and/or biologically active proteins such as growth factors. The collagen-polymer conjugates of the invention generally contain large amounts of water when formed. The conjugates can be dehydrated to form a relatively solid object. The dehydrated, solid object can be ground into particles which can be suspended in a non-aqueous fluid such as an oil and injected into a living being for the purpose of providing soft tissue augmentation. Once in place, the particles rehydrate and expand in size five fold or more.

Abstract translation: 药学上可接受的非免疫原性组合物通过经由特定类型的化学键共价结合肽肽胶原与药学​​纯合成的亲水性聚合物形成，以提供胶原/聚合物共轭物。 糖尿病胶原可以是I型，II型或III型，并且可以是纤维状或非纤维状的。 合成亲水性聚合物可以是重均分子量在约100至约20,000范围内的聚乙二醇及其衍生物。 组合物可以包括其它组分，例如液体，药学上可接受的，载体以形成可注射制剂，和/或生物活性蛋白质例如生长因子。 当形成时，本发明的胶原 - 聚合物共轭物通常含有大量的水。 可以将共轭物脱水形成相对固体的物体。 脱水的固体可以被研磨成可以悬浮在诸如油之类的非水性流体中的颗粒，并注入活体以提供软组织增加。 一旦就位，颗粒再水合并扩大五倍以上。